- Cascades Inc. CAS CADNF price target has been lowered to C$15 from C$17 by RBC Capital analyst Paul C. Quinn after the Q1 results.
- The analyst maintained the Outperform rating on the shares.
- Quinn mentions that the company reported 1Q22 Adjusted EBITDA of $58 million, which was well below their $89 million forecast and consensus of $90 million.
- Shares were down ~23% following the release of results. Quinn thinks that demonstrating improving performance in the Tissue business will be critical over the next couple of quarters.
- Price Action: CAS shares are trading higher by 7.10% at C$9.81 on TSX, and CADNF is higher by 11.97% at $7.86 on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
